Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Non-current Assets
All assets not expected to be converted to cash within one year.
Evommune, Inc.NYSE: EVMN
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 6207.7% from a year ago
Total non-current assets stood at $106.6M at the end of Q1 FY2026, up 6207.7% from a year earlier and up 49.2% from the prior quarter.
Context
- Total non-current assets amounted to 33.1% of total assets at the end of Q1 FY2026, up 30.0 pp from a year earlier.
- Total non-current assets increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +6207.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 71.47M USD
- Year-over-year change
- +3357.6%
- 2-year CAGR
- +467.8%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.47M | +3357.6% |
| FY2024 | 2024-12-31 | 2.07M | -6.8% |
| FY2023 | 2023-12-31 | 2.22M | — |
Total Non-current Assets vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total non-current assets of $106.6M is the 5th highest of the 10 companies compared; the peer median is $49.72M.
- Its year-over-year change of +6207.7% is the highest of 10, against a peer median of -4.5%.
- Total non-current assets amounts to 33.1% of total assets for EVMN, versus a peer median of 33.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $1.79B | -4.5% | -15.8% | 66.0% |
| Jun 2026 | $728.76M | +22.3% | +13.4% | 33.3% | |
| Sep 2026 | $644.02M | +510.1% | +2.8% | 54.7% | |
| Mar 2026 | $228.53M | -9.5% | -7.4% | 77.8% | |
EVMNEvommune, Inc. | Mar 2026 | $106.6M | +6207.7% | — | 33.1% |
| Mar 2026 | $49.72M | -2.7% | -16.5% | 38.4% | |
CLYMClimb Bio, Inc. | Mar 2026 | $38.97M | -61.2% | +369.3% | 25.6% |
| Mar 2026 | $38.71M | +8.8% | +67.3% | 13.4% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $17.22M | -19.0% | -13.6% | 16.2% |
| Mar 2026 | $5.08M | -32.0% | -13.0% | 3.9% | |
| Peer median (excluding EVMN) | $49.72M | -4.5% | -7.4% | 33.3% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.